In MM, low RASSF4 expression predicts a poor prognosis, as it activates pro-apoptotic pathways (MST1, JNK/c-Jun, and p38) and inhibits pro-survival pathways (MEK/ERK and PI3K/mTOR/Akt), leading to cell cycle arrest and apoptosis and enhancing the efficacy of targeted drug therapy [16]. Here, JUN is linked to Miyoshi myopathy.